Developing therapies to improve quality of life in Alzheimer's disease
Established in 2016 in Heidelberg (Germany), EXCIVA is a privately held biotech company focused on developing clinical stage therapeutics for various indications in neuropsychiatry.
Our mission is to develop a groundbreaking therapy that effectively and safely addresses neuropsychiatric symptoms of dementia including agitation/aggression in Alzheimer’s disease dementia read more
January 20, 2026
Exciva raises €51 million
Exciva GmbH today announces the closing of a €51 million ($59m) Series B financing round.
February 12, 2025
New HCO
Fiona Hattey joined the Exciva team as Head of Clinical Operations. She has over thirty years of experience in operationalizing clinical trials.
November 4, 2024
Fast Track Designation
Our lead program, EXV-802 for the treatment of agitation in dementia associated with Alzheimer’s disease, received a Fast Track designation from the US FDA
Our vision
We aim to improve the quality of life and independence of patients, reduce distress for caregivers and support patients' families. Through cutting-edge research, rigorous clinical trials and collaboration with experts, we are dedicated to delivering the first-in-class and best-in-class treatments for neuropsychiatric symptoms of dementia.
Our ultimate vision is to restore dignity and quality of life of individuals affected by neuropsychiatric symptoms of dementia , provide comprehensive relief, and help transform the way dementia care is perceived and managed worldwide.